CARE Ratings has downgraded Nova Agritech Ltd and its subsidiary to 'CARE BBB-; Stable' from 'CARE BBB; Negative'. The revision stems from a sharp decline in operating margins and increased working capital stress. While the firm maintains a low debt profile, investors should track improvements in collection efficiency and liquidity management as regulatory hurdles in the bio-stimulants segment impact recent performance.
Nova Agritech Credit Rating Downgraded to CARE BBB-
Consolidated PBILDT margin dropped to 10.45% in FY26 from 14.51% in FY25.
Consolidated operating cycle elongated to 295 days from 217 days in the previous year.
Reader Takeaway: Regulatory headwinds caused temporary operational disruption, though the company maintains a low-geared balance sheet for long-term stability.
What just happened
CARE Ratings has downgraded the long-term bank facilities of Nova Agritech Limited and its material subsidiary, Nova Agri Sciences Private Limited, to 'CARE BBB-; Stable'. The revision reflects a combination of moderating financial performance and mounting liquidity pressures. The company reported a decline in total operating income to Rs 261.59 crore in FY26, down from Rs 294.13 crore in FY25.
Why this matters
The rating action highlights a period of structural volatility. A primary driver was a government-imposed stay on bio-stimulants starting in July 2025, which severely restricted a high-margin product category. Although the company secured approvals for 43 products in January 2026, the resulting supply chain disruption hit the bottom line, with PAT falling from Rs 27.42 crore to Rs 12.84 crore year-on-year.
Liquidity and Working Capital Stress
Liquidity is currently classified as 'stretched'. The company's operating cycle has worsened significantly, rising to 295 days. A critical concern for investors is the status of receivables; approximately 48% of outstanding amounts were overdue for over six months as of March 31, 2026. Furthermore, nearly 96% utilization of fund-based working capital limits leaves minimal room for financial maneuverability.
What looks positive
Despite the downgrade, the group maintains a healthy capital structure. Overall gearing improved to 0.22x in FY26 from 0.25x in FY25. Debt protection metrics remain decent, with interest coverage at 5.63x. The firm also continues to leverage a robust distribution network spanning 6,000 dealers across 18 Indian states.
What to track next
Shareholders should monitor the company's ability to shorten the collection period and reduce reliance on short-term bank debt. The successful scaling of the newly approved bio-stimulant portfolio will be a vital indicator of whether the firm can restore its historical margin profile.